Our Checkbooks are Sexist and It is Killing My Friends

I was sitting with my friend Sarah last Tuesday - she drinks kale juice like it is a revolutionary act - when she mentioned her oncology bill. (We were at that Italian place where the waiters treat you like a burden they are forced to carry.) Sarah has fought uterine cancer for three years. She notes that if men had a body part so prone to lethal revolt, we would have a cure by now. She is correct. I spilled my wine and I do not even care about the rug. (Waiters be damned.)

The math is frankly offensive. A 2020 study in the Journal of Women's Health proved that cancers like ovarian and uterine receive funding that is insulting compared to their death rates¹ [Source: Journal of Women's Health, 2020]. It is not a minor oversight. It is a failure of imagination. (I find it stomach-turning that we calculate the value of a sister in a spreadsheet, but here we are.) The budget for these diseases is a tip jar compared to the mountains of cash elsewhere. It is not just a budget gap. It is a canyon in our priorities.

The Pipeline is Bone Dry

When the money stops flowing, the science dies on the vine. It is that simple. Innovation does not just slow down; it effectively disappears. The gears of progress simply seize up. (Academic leaders prefer funding safe, boring studies that protect their tenure tracks.) My neighbor Diane drove through three states to find a clinical trial because her local hospital had nothing to offer her. This is the reality of underfunding: it creates a geographic and financial barrier to survival. As we enter 2026, the fact that your zip code determines your life expectancy is a national disgrace.

We are caught in a cycle where a lack of cash prevents the breakthroughs that would justify more cash. It is a circular logic that carries a body count. For many gynecological cancers, there is no Pap smear equivalent. We have nothing. Doctors call ovarian cancer a quiet predator because it hides until it is far too late. Why do we not have better screening? Because we have decided this is not a priority. (I am getting angry just typing this, and I have not even finished my second glass of wine.)

The Human Cost of Bureaucratic Indifference

My friend Sarah often jokes that she is navigating a labyrinth designed by someone who hates women. The protocols are ancient. This means many women are still treated with chemotherapy that has not changed since the Nixon administration. It is, quite frankly, embarrassing for a nation that prides itself on being at the forefront of medical innovation. (We can put a billionaire in space for five minutes, but we cannot figure out how to screen for uterine cancer.)

We need to stop pretending this is a natural phenomenon. It is a choice. Every time a budget is passed that ignores these cancers, a choice is being made. I checked the numbers twice because I did not want to believe they were that lopsided. They are. We are failing our sisters, our mothers, and our friends because we lack the political will to demand better. It is not complicated. It is just wrong.

The Economic and Moral Imperative for Equity

If the moral argument does not move the needle for you, perhaps the cold, hard economic data will. (Money is the only language some of our institutions speak fluently.) When we fail to fund research into uterine or cervical cancers, we are not just failing individuals; we are sabotaging the workforce. Leading cancer advocacy groups note that these diseases hit women in their professional prime² [Source: Major Health Organization, 2024]. These are women raising families, leading companies, and fueling the tax base. (I checked the reports and the numbers are staggering.)

The loss of life and productivity costs the global economy billions of dollars every single year³ [Source: Global Health Report, 2021]. A 2021 report highlighted that uterine cancer incidence is actually rising, particularly among women of color, yet research funding has not mirrored this trend. (It is almost as if the system is designed to ignore the people who need it most, but surely that is just a coincidence.) We are seeing a disturbing rise in mortality for uterine cancer, which is one of the few cancers where the death rate is actually getting worse⁴ [Source: National Cancer Institute, 2023]. This is a massive red flag. By 2026, we should be past the stage where we treat this like a footnote while holding pink-themed galas where everyone eats rubbery chicken and feels good about awareness.

The moral imperative here is clear: we cannot claim to be a society that values health equity while systematically underfunding the diseases that affect half the population. I have seen enough awareness months to last me a lifetime; what I want to see is a line item in a federal budget that actually reflects the scale of the problem. Institutional change requires more than just good intentions. It requires a radical restructuring of how we prioritize research grants. I spoke to a colleague recently who assumed that because these diseases are so well-known, they must be well-funded. (Assumption is the mother of all systemic failures.) This misconception is part of the problem. People see the ribbons and the walks and assume the heavy lifting is being handled.

How to Pivot Toward a Just Future

So, where do we go from here? (Ideally, somewhere with a significantly larger research budget and fewer medical euphemisms.) The first step is transparency. We need to demand that the NCI and other funding bodies provide clear, accessible reports on how their dollars are allocated relative to disease burden. If a cancer kills 15,000 women a year but receives less funding than a cancer that kills 5,000, we deserve to know why. (Pressure is the only thing that works when dealing with slow-moving bureaucracies that have the agility of a glacier.)

We need to advocate for specific legislation in 2026 that earmarks funds for under-researched female cancers. It is not enough to hope that committees will eventually do the right thing; we must make the right thing the only thing they are allowed to do. Beyond the financial side, we must broaden our definition of women's health past the reproductive years. Many gynecological cancers are diagnosed post-menopause, yet research often focuses on younger demographics. My Aunt Linda was sixty-eight when she was diagnosed, and she felt like she had been aged out of the medical system's concern. We must ensure that research funding covers the entire lifespan of a woman. This means investing in geriatric oncology and understanding how these diseases interact with the aging process⁵ [Source: Public Health Mortality Trends Study, 2022].

If you cannot run a lab, you cannot find a cure. By increasing institutional funding, we create a stable environment where the brightest minds can tackle these complex diseases without worrying if their electricity will be turned off next Tuesday. (And if we can afford to spend billions on space tourism for people who are already bored of Earth, we can surely afford to fund a few more labs.)

Myth vs. Fact

Myth: Gynecological cancers receive funding proportional to their impact on the population.

Fact: A 2020 study in the Journal of Women's Health confirmed that ovarian and uterine cancers are significantly underfunded relative to their mortality rates compared to other cancers.

Frequently Asked Questions

❓ Why is there a funding gap for gynecological cancers compared to other types?

The short answer surprises most people: it is a toxic mixture of historical exclusion and a clinical focus on more visible or common cancers. (We spent decades pretending that women were just smaller versions of men, and we are finally paying the price for that ignorance.)

❓ What happens to treatment when research is not funded?

When research is not funded, new drugs do not make it to the pharmacy shelf. This means that many women are still being treated with chemotherapy protocols that have not changed significantly in decades. It also means fewer clinical trials, which are often the last hope for patients with advanced disease.

❓ Does where you live affect your survival chances?

It absolutely does. If you live outside a major metropolitan area, your access to the latest innovations in gynecological oncology is likely severely limited because the funding to expand those programs simply does not exist. (It is a tragedy of geography that we should have solved a long time ago.)

❓ Why is uterine cancer specifically becoming more dangerous?

The incidence of uterine cancer is rising, and for reasons we do not fully understand yet - likely due to a lack of research - the mortality rates are actually worsening for certain demographics. This is a public health emergency that is currently being treated like a footnote.

❓ What can individuals do to help shift institutional priorities?

This depends on your situation, but the most effective tool we have is political advocacy. You should reach out to your representatives and demand that they support increased funding for the National Cancer Institute specifically for gynecological cancer research. When enough people start asking uncomfortable questions about budget allocations, the people in charge of those budgets usually start listening.

References

Disclaimer: This article is for informational purposes only and does not constitute medical advice. The views expressed here are based on editorial analysis of public health funding and available research. Always consult with a qualified healthcare professional regarding any specific medical concerns or diagnostic treatment options.